The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting

Clinical Infectious Diseases

Volumn 55, Issue 12, 2012, Pages 1690-1697

  Geng, Elvin H ^a   Hare, C Bradley ^a   Kahn, James O ^a   Jain, Vivek ^a   Van Nunnery, Tracy ^a   Christopoulos, Katerina A ^a   Deeks, Steven G ^a   Gandhi, Monica ^a   Havlir, Diane V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PUBLIC HEALTH; RNA, VIRAL; VIRAL LOAD;

EID: 84870170582     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis750     Document Type: Article

References (24)

1. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-61.
2. Mugavero MJ, Napravnik S, Cole SR, et al. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011; 53:927-35.
3. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2011; 24:1897-1905.
4. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-44.
5. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.
6. Nelson M, Girard PM, Demasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother 2010; 65:1505-9.
7. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
8. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Edited by DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents OoARAC. Washington, D.C.: Department of Health and Human Services; 2007.
9. Russell S. City endorses new policy for treatment of H.I.V. New York Times, 3 April 2010.
10. Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis 2011; 53:600-4.
11. Mayer KH. Linkage, engagement, and retention in HIV care: Essential for optimal individual-And community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis 2011; 52 (suppl 2):S205-7.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2011: 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdoles centGL.pdf. Accessed 5 April 2012.
13. Riley ED, Moore K, Sorensen JL, Tulsky JP, Bangsberg DR, Neilands TB. Basic subsistence needs and overall health among human immunodeficiency virus-infected homeless and unstably housed women. Am J Epidemiol 2011; 174:515-22.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958; 53:457-81.
15. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. The Stata Journal 2004; 4:103-112.
16. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91:1229-35.
17. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-6. (Pubitemid 38405384)
18. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15:615-25.
19. Gandhi M, Ameli N, Bacchetti P, et al. Eligibility criteria for HIV clinical trials and generalizability of results: The gap between published reports and study protocols. AIDS 2005; 19:1885-96.
20. Reif S, Thomas CP, Wallack SS. Factors determining how early adopter physicians use buprenorphine in treatment. J Addict Med 2007; 1:205-12.
21. Sheikh A, Cornford T, Barber N, et al. Implementation and adoption of nationwide electronic health records in secondary care in England: Final qualitative results from prospective national evaluation in "early adopter" hospitals. BMJ 2011; 343:d6054.
22. Lomas J, Enkin M, Anderson GM, Hannah WJ, Vayda E, Singer J. Opinion leaders vs audit and feedback to implement practice guidelines: Delivery after previous cesarean section. JAMA 1991; 265:2202-7.
23. Cheever LW. Engaging HIV-infected patients in care: Their lives depend on it. Clin Infect Dis 2007; 44:1500-2. (Pubitemid 46801596)
24. Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: Piecing together the fragments of a fractured health care delivery system. Clin Infect Dis 2011; 52 (suppl 2):S238-46.